🇺🇸

US SEC Filing Intelligence

· daily

General Federal Contracts — April 04, 2026

NASA's Goddard Space Flight Center has obligated $181,839,613 to The Leland Stanford Junior University for the Solar Dynamics Observatory Project Heliospheric and Magnetic Imager (HMI) investigation, representing 100% of the period's aggregate value with zero defense-related contracts. This single civilian award underscores a long-term commitment to space science R&D under a definitive cost-no-fee structure awarded in 2002 and extending to 2027-09-30. The highest-conviction signal is neutral (4/10 strength), reflecting steady multi-decade funding despite only $25,928,889 outlayed to date against a base + options value of $186,336,824. Full and open competition signals no immediate moat concerns, with low pricing risk. A key watch item is outlay progress and performance milestones toward the 2027 end date amid potential uneven R&D spending.

1 total filings
· daily

All NASA Contracts — April 04, 2026

NASA's single contract obligation of $181,839,613 during April 04, 2026, to April 04, 2026, is fully civilian with zero defense-related awards, centered on Goddard Space Flight Center's long-term space science R&D funding. The Leland Stanford Junior University received the entirety for the Solar Dynamics Observatory Project Heliospheric and Magnetic Imager (HMI) investigation, a 25-year cost-no-fee contract (2002-2027) under full and open competition. The highest-conviction signal is neutral (4/10 strength), reflecting stable but low outlays of $25,928,889 against a base + options value of $186,336,824. Dominant theme is sustained NASA commitment to heliophysics R&D via academic partners. Key risk/watch item: monitor outlay progression beyond $25.9M and performance toward the 2027-09-30 end date amid uneven spending.

1 total filings
· daily

Biotech Small-Cap Approvals — April 03, 2026

The FDA approved 7 'Other' products from March 27-31, 2026 (captured in the April 03 period), featuring 0 NMEs, 0 biosimilars, and 0 label expansions, with all signals rated neutral due to generic/ANDA or standard original approvals lacking premium designations. No dominant therapeutic area theme is evident, as indications remain unspecified across the board. Highest-conviction signal is TEVA PHARMACEUTICALS, INC.'s original BLA 761385 approval (materiality 4/10), a modest portfolio addition for the sponsor with low pricing power and no exclusivity. Key risk/watch item is negligible commercial differentiation in crowded generic markets, with post-approval launches as the sole near-term catalysts.

7 total filings
· daily

NME Blockbuster Approvals — April 03, 2026

The FDA approval period of April 3 to April 3, 2026, featured 1 other approval (0 NMEs, 0 biosimilars, 0 label expansions), centered on ELI LILLY AND CO's Unknown under Priority Review. No dominant therapeutic area theme is evident due to undisclosed details. The highest-conviction signal is ELI LILLY AND CO's Unknown NME approval, a bullish event (strength 8/10, materiality 8/10) signaling pipeline execution and potential commercial upside in the NME Blockbuster Approvals stream. Priority Review designation highlights FDA recognition of significant benefit. Key risk/watch item: Limited visibility into peak sales, exclusivity, pricing, and market position (all NOT_DISCLOSED), warranting post-approval commercialization monitoring.

1 total filings
· daily

Big Pharma Approvals — April 03, 2026

This period features 4 Other approvals (0 NME, 0 biosimilar, 0 label expansion), with a focus on rare disease assets underscored by Orphan Drug designations. Vertex Pharmaceuticals dominates with two Priority Review supplemental NDA approvals for TRIKAFTA (ELEXACAFTOR, IVACAFTOR, TEZACAFTOR), signaling label enhancements in cystic fibrosis and reinforcing franchise strength. Highest-conviction signal is Eli Lilly and Co's NME approval for Unknown under Priority Review, a bullish execution milestone with potential 5-year exclusivity despite undisclosed commercial details. Biogen Inc's Nusinersen Sodium approval is neutral with limited data. Key risk/watch item: Uncertain label details and post-approval uptake for Vertex supplements; full commercial profile for Lilly's Unknown remains NOT_DISCLOSED.

4 total filings
· daily

Orphan Drug Approvals — April 03, 2026

This period's 6 Orphan Drug approvals consist of 0 NMEs, 0 biosimilars, 0 label expansions, and 6 other approvals, with 3 bullish, 0 bearish, and 3 neutral signals. Vertex Pharms Inc dominates with two Priority Review supplemental approvals for TRIKAFTA (ELEXACAFTOR, IVACAFTOR, TEZACAFTOR), signaling strong label enhancement potential in orphan indications and reinforcing its franchise execution. Acadia Pharms Inc's TROFINETIDE supplemental approval adds a moderate bullish catalyst via Priority Review and Orphan exclusivity. No dominant therapeutic area theme emerges from available data; key watch item is post-approval label details and uptake for Vertex and Acadia amid unknown indication specifics.

6 total filings
· daily

New Drug Approvals (Original) — April 03, 2026

This week's 8 FDA approvals under New Drug Approvals (Original) stream comprise 0 NMEs, 0 biosimilars, 0 label expansions, and 8 others, dominated by generic ANDA entries and standard original NDAs/BLAs with neutral investment implications due to lack of premium designations and unspecified therapeutic areas. No dominant therapeutic area theme emerges as indications are largely not specified. Highest-conviction signal is Eli Lilly and Co's Unknown NME approval under Priority Review, indicating strong unmet need and potential 5-year exclusivity as a first-in-class commercial catalyst. Key risk/watch item is generic erosion from multiple ANDA approvals (e.g., MESALAMINE by KLM Labs Pvt, BENZONATATE by Marksans Pharma), though limited by unknown market sizes.

8 total filings
· daily

New Federal Contractors — April 03, 2026

These five new federal contracts total $2,789,953,840 in obligations, entirely civilian with zero defense-related awards, highlighting robust non-DOD spending. Dominant themes include a massive $2.01B Department of Energy award to WASHINGTON TRU SOLUTIONS LLC and Department of Education commitments to student loan servicing via NELNET SERVICING LLC ($200.3M) and MAXIMUS EDUCATION LLC ($164.8M). Highest-conviction signal is the bullish $200.3M NELNET SERVICING LLC award (strength 8/10, materiality 9/10) under full and open competition for future revenue starting 2026-04-01. CGI FEDERAL INC. secures two awards totaling $417M across HHS and State for IT services. Key risk is zero outlays to date on three high-materiality Education and DOE contracts, with dependency on options exercise for full value realization.

5 total filings
· daily

Significant Contract Modifications ($10M+) — April 03, 2026

Five significant civilian contract modifications totaling $2,789,953,840 (0/5 defense-related) highlight steady federal IT and financial services spending, led by Washington Tru Solutions LLC's massive $2.01B Department of Energy award and Department of Education's $365M in student loan servicing to Nelnet Servicing LLC ($200.3M) and Maximus Education LLC ($164.8M). The highest-conviction signal is bullish for Nelnet Servicing's $200.3M award (strength 8/10, materiality 9/10), representing a future revenue stream starting April 2026 under full and open competition. CGI Federal Inc. captures $417M across HHS ($261.9M neutral Medicare IT) and State Department ($155.1M bullish consular IT). Dominant theme is civilian education financial services growth. Key risk: high pricing risk on fixed-price structures for CGI HHS and Maximus Education, with options exercise critical to unlocking full ceilings over $650M combined.

5 total filings
· daily

Contract Deobligations Alert — April 03, 2026

This Contract Deobligations Alert covers $2,789,953,840 in total obligations across 5 civilian contracts (0 defense-related) from April 03, 2026, spanning DOE, HHS, Education, and State. Dominant themes include massive DOE nuclear waste management via WASHINGTON TRU SOLUTIONS LLC ($2.01B) and Department of Education student loan servicing awards to NELNET SERVICING LLC ($200.3M) and MAXIMUS EDUCATION LLC ($164.8M). Highest-conviction bullish signal is NELNET SERVICING LLC's $200.3M task order (strength 8/10, materiality 9/10) signaling stable future revenue from 2026-04-01. CGI FEDERAL INC. shows repeat exposure with $261.9M HHS and $155.1M State contracts. Key risk is high pricing risk on fixed-price structures for CGI and MAXIMUS contracts, with watch on option exercises and outlay progress from current $0 on new Education awards.

5 total filings
· daily

Contract Option Exercises — April 03, 2026

These five contract option exercises total $2,789,953,840 in obligations, entirely civilian with 0/5 defense-related, highlighting steady federal spending outside DOD amid CR risks. Dominant themes include Department of Energy's massive $2.01B award to WASHINGTON TRU SOLUTIONS LLC and Department of Education's $365M combined commitment to student loan servicing via NELNET SERVICING LLC ($200.3M) and MAXIMUS EDUCATION LLC ($164.8M). Highest-conviction signal is NELNET SERVICING LLC's bullish $200.3M award (strength 8/10, materiality 9/10) under full and open competition for future revenue starting April 2026. CGI FEDERAL INC. captures two IT services awards totaling $417M from HHS and State Department, signaling multi-agency revenue diversification. Key watch item: zero outlays to date on new Education contracts, with risks tied to options exercise and performance through 2027-2033.

5 total filings
· daily

Federal IT & Cybersecurity Contracts — April 03, 2026

CGI Federal Inc. secured $416,973,187 in total obligations across two civilian federal IT contracts, with zero defense exposure, highlighting steady revenue in healthcare and diplomatic IT services. The dominant theme is long-term IT systems support for HHS Centers for Medicare and Medicaid Services ($261.9M PECOS enrollment system) and Department of State consular operations in China ($155.1M computer facilities management). The highest-conviction bullish signal stems from the $155.1M State Department award (materiality 8/10), signaling revenue stability through 2024-12-31 with potential upside to $218.6M via options. The HHS contract adds neutral stability but carries high pricing risk under firm fixed price terms. Key watch item: option exercises and outlay progress on both, with HHS extending potentially to 2027-02-28.

2 total filings
· daily

All HHS Contracts — April 03, 2026

The analyzed contracts total $261,858,878 in obligations across 1 HHS award to CGI Federal Inc., representing 100% civilian activity with 0 defense-related contracts. Dominant agency is HHS's Centers for Medicare and Medicaid Services (CMS), focused on long-term IT support for the PECOS Medicare enrollment system under a 2016 firm fixed price delivery order. $112,554,296 has been outlayed to date, leaving ~$149M in remaining obligations through current end 2026-11-30 and potential 2027-02-28, equating to steady ~$23-24M annual revenue. The highest-conviction neutral signal (5/10 strength, 6/10 materiality) highlights stable government IT revenue in healthcare admin. Key risk is high pricing risk from the firm fixed price structure, with watch on option exercise to $264.3M ceiling.

1 total filings
· daily

All DOE Contracts — April 03, 2026

DOE obligated $2,007,900,739 across one contract in this period, representing 100% civilian spending (0/1 defense-related). WASHINGTON TRU SOLUTIONS LLC captured the entirety of this award, a bullish signal with 7/10 strength and 8/10 materiality. The dominant agency theme is DOE procurement sustainment via large legacy obligations. Highest-conviction signal is bullish backlog addition for WASHINGTON TRU SOLUTIONS LLC. One key risk is unknown competition signal and pricing risk, warranting watch for re-compete vulnerability on this 2000-dated contract.

1 total filings
· daily

Mega Contracts Monitor ($100M+) — April 03, 2026

These five mega civilian contracts total $2,789,953,840 in obligations with 0/5 defense-related, underscoring robust non-DOD federal spending amid zero DOD exposure. Dominant agency theme is Department of Education student loan servicing with $365M combined to Nelnet Servicing LLC ($200.3M) and Maximus Education LLC ($164.8M), both bullish future streams starting April 2026. Highest-conviction signal is Nelnet Servicing LLC's $200.3M award (strength 8/10, materiality 9/10) under full open competition. Washington TRU Solutions LLC dominates value at $2.01B DOE bullish award, dwarfing others despite sparse details. Key risk/watch item: $0 outlays to date on new Education contracts, hinging on options exercise (e.g., Nelnet to 2027-12-31, Maximus to $376M ceiling through 2033-04-24).

5 total filings
· daily

High-Value Federal Grants ($5M+) — April 03, 2026

These five high-value federal grants totaling $2,789,953,840 are entirely civilian (0/5 defense-related), dominated by Department of Energy ($2.01B to WASHINGTON TRU SOLUTIONS LLC) and Department of Education student loan servicing awards ($365M combined to NELNET SERVICING LLC and MAXIMUS EDUCATION LLC). The highest-conviction bullish signal is NELNET SERVICING LLC's $200.3M award (materiality 9/10, strength 8/10) for future student loan operations starting April 2026 with potential extension to 2027. CGI FEDERAL INC. appears twice for IT services at HHS ($261.9M) and State ($155.1M), signaling multi-agency IT stability. Key watch item is options exercise and outlay progress, as three contracts have $0 outlayed despite high future ceilings.

5 total filings
· daily

DOE Energy Grants — April 03, 2026

The DOE Energy Grants stream obligated $2,007,900,739 across one civilian contract, with zero defense-related awards out of one total. WASHINGTON TRU SOLUTIONS LLC received the full $2.01B award from the Department of Energy, representing a dominant theme in civilian energy sector funding. The highest-conviction signal is bullish for WASHINGTON TRU SOLUTIONS LLC at 7/10 strength and 8/10 materiality, highlighting sustained DOE commitment via this large-scale obligation. No bearish signals emerged, but a key risk watch item is the absence of disclosed data on annual revenue impact, contract pricing risk, or competition status for this 2000-dated award. Investors should monitor DOE energy services for similar civilian infusions, differentiating from defense volatility.

1 total filings
· daily

General Federal Contracts — April 03, 2026

These five civilian contracts total $2,789,953,840 in obligations, with 0/5 defense-related, dominated by a massive $2.01B Department of Energy award to WASHINGTON TRU SOLUTIONS LLC and a cluster of student loan servicing deals at the Department of Education totaling $365M to NELNET SERVICING LLC ($200.3M) and MAXIMUS EDUCATION LLC ($164.8M). CGI FEDERAL INC. secures steady IT revenue across HHS ($261.9M PECOS system) and State ($155.1M consular IT), highlighting multi-agency exposure. Highest-conviction signal is the bullish $200.3M NELNET SERVICING LLC student loan servicing award (strength 8/10, materiality 9/10) signaling future revenue from 2026-04-01. Key risk is zero outlays to date on the new Education contracts, with dependency on options exercise for full value realization.

5 total filings
· daily

S&P 500 Technology Sector SEC Filings — April 03, 2026

Across the 7 filings in the S&P 500 Technology stream (though skewed toward small-cap biotech, financials, and niche players), dominant themes include proxy statements for upcoming annual meetings (Aditxt, Camden), leadership compensation updates (Radian), auditor changes (Arcadia), shelf registrations for resale (Lyell), institutional portfolios (Adirondack), and stark financial deterioration (Token). Period-over-period trends reveal acute weakness in Token Communities with revenues plunging 85% YoY to $356k, gross margins collapsing 98% to $18k, and net loss of $464k vs prior profit, contrasting neutral stability elsewhere; no broad tech margin compression or growth patterns emerge due to diverse/non-core filers. Critical developments include Arcadia's auditor dismissal amid going concern warnings and material control weaknesses, signaling distress in ag-biosciences, while Aditxt's reverse split authorization flags liquidity risks. Portfolio-level patterns show proxy season catalysts in May 2026, limited insider conviction (none reported), and Adirondack's heavy tech exposure (Apple, Amazon). Market implications: Low conviction for tech longs, heightened risks in small caps, monitor governance votes for alpha.

3 high priority 4 medium 7 total filings
· daily

Nasdaq 100 Stocks SEC Filings — April 03, 2026

Proxy season is accelerating across NASDAQ-100 related filings with four companies (Mondelez, Aditxt, Camden National, Radian implied via comp) scheduling virtual annual meetings in May 2026, focusing on director elections, say-on-pay, auditor ratifications, and reverse splits. Period-over-period trends reveal stark contrasts: Token Communities suffered an 85% YoY revenue plunge to $356k, 87% drop in home sales, and gross margins shriveled 98% to $18k, while Mondelez reported solid 2025 net revenue growth and strong FCF amid cocoa volatility. Exec transitions signal caution—Intel's EVP/Chief Legal Officer exit effective June 1, 2026 (negative), contrasted by Radian's new Interim CFO compensation package ($500k base, $1M LTIP). Arcadia Biosciences' auditor switch highlights ongoing distress with going concern warnings and material control weaknesses from Dec 31, 2025 10-K. Lyell's S-3 enables resale of 1.95M shares from $25.61 milestone pricing (premium to $13.32 initial), potentially pressuring supply. Overall themes: resilient consumer staples (MDLZ) vs. biotech/small-cap distress (ADTX, LYEL, RKDA, TKCM), with limited capital allocation or insider trading signals but high event density for catalysts.

5 high priority 5 medium 10 total filings